Document Detail

16-Gy Low-Voltage X-ray Irradiation With Ranibizumab Therapy for AMD: 6-Month Safety and Functional Outcomes.
MedLine Citation:
PMID:  21830747     Owner:  NLM     Status:  Publisher    
BACKGROUND AND OBJECTIVE:To describe the 6-month safety and preliminary efficacy outcomes of the use of 16-Gy radiation with intravitreal ranibizumab for patients with neovascular age-related macular degeneration (AMD). PATIENTS AND METHODS:A single treatment of a non-invasive, externally delivered low-voltage 16-Gy x-ray irradiation was administered in one session through three locations in the inferior pars plana. Optical coherence tomography (OCT) and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) examinations were performed at 1 week, 1 month, and monthly thereafter, with quarterly fluorescein angiography (FA). After the two initial ranibizumab injections, subsequent injections were administered according to the following criteria: VA decline of 10 ETDRS letters compared with baseline, increase of 100-μm central foveal thickness on OCT compared with baseline, the development of new submacular hemorrhage, and the development of a new area of classic choroidal neovascularization on FA. RESULTS:Twenty-six patients completed a 6-month follow-up. There was no evidence of radiation retinopathy, optic neuropathy, or cataract. The mean baseline ETDRS score was 46.6 letters (range: 5 to 80; standard deviation [SD]: 21.5). At 6 months, the corresponding ETDRS score was 55.6 letters (range: 25 to 80; SD: 18.9) and the mean change in VA was 9.5 ETDRS letters (SD: 10.3). On responder analysis, 96% lost 15 or fewer ETDRS letters, 81% gained 0 or more ETDRS letters, and 50% gained 15 or more ETDRS letters. Patients received a total of 13 ranibizumab injections following two initial injections. At 6 months, patients received an average of 0.5 additional injections following the initial two mandated injections. CONCLUSION:A single treatment of externally applied, non-invasive 16-Gy low-voltage x-ray therapy in conjunction with ranibizumab demonstrated an overall improvement of VA in patients with neovascular AMD at 6 months with no radiation-related adverse effects.
Virgilio Morales Canton; Hugo Quiroz-Mercado; Raul Velez-Montoya; Miriam J Lopez-Miranda; Andrew A Moshfeghi; Eugene M Shusterman; Peter K Kaiser; Steven R Sanislo; Michael Gertner; Darius M Moshfeghi
Related Documents :
23367677 - Botulinum toxin type a and neurogenic urinary incontinence: sometimes beneficial, if us...
11398557 - A longitudinal evaluation of craniofacial growth in a patient with kabuki make-up syndr...
23738147 - Assessment of the effects of access count in percutaneous nephrolithotomy on renal func...
10196817 - Morphologic changes in the upper airway structure following surgical correction of mand...
2243307 - Impact on patient care. 2652 pic catheter days in the alternative setting.
22114587 - Rifaximin is effective for the treatment of clostridium difficile-associated diarrhea: ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-11
Journal Detail:
Title:  Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye     Volume:  -     ISSN:  1938-2375     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-8-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101155780     Medline TA:  Ophthalmic Surg Lasers Imaging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-6     Citation Subset:  -    
Copyright Information:
Copyright 2011, SLACK Incorporated.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Spectral-Domain Optical Coherence Tomography as a Screening Technique for Chloroquine and Hydroxychl...
Next Document:  Intraoperative spectral-domain optical coherence tomography during complex retinal detachment repair...